Source:http://linkedlifedata.com/resource/pubmed/id/16152762
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2005-9-12
|
| pubmed:abstractText |
The aetiological agent for severe acute respiratory syndrome (SARS) has been determined to be a new type of coronavirus (SARS-CoV) that infects a wide range of mammalian hosts. Up to now, there have been no specific drugs to protect against SARS-CoV infection, thus developing effective strategies against this newly emerged viral infection warrants urgent efforts. Adoptive immune therapy with pathogen-specific heterologous immunoglobulin has been successfully used to control the dissemination of many viral infections. To investigate whether a neutralizing antibody against SARS-CoV raised in an artiodactylous host can have a protective role on primate cells, we prepared serum IgGs and their pepsin-digested F(ab')2 fragments from horses inoculated with purified SARS-CoV (BJ-01 strain). The protective effect of the F(ab')2 fragments against SARS-CoV infection was determined in cultured Vero E6 cells by cytopathic effect (CPE), MTT and plaque-forming assays and in a Balb/c mouse model by CPE and quantitative RT-PCR. The results showed the neutralization titres of F(ab')2 from three horses all reached at least 1:1600, and 50 microg of the F(ab')2 fragments could completely neutralize 1x10(4) TCID50- SARS-CoV in vivo. Additionally, we observed that F(ab')2, against BJ-01 strain could also protect cells from infection by the variant GZ-01 strain in vitro and in vivo. Our work has provided experimental support for testing the protective equine immunoglobulin in future large primate or human trials.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1359-6535
|
| pubmed:author |
pubmed-author:DuXinanX,
pubmed-author:GaoWendaW,
pubmed-author:HeYangdongY,
pubmed-author:JiangHaiyanH,
pubmed-author:JiangManM,
pubmed-author:LiWanlingW,
pubmed-author:LiXingX,
pubmed-author:LuoDeyanD,
pubmed-author:MaoLiweiL,
pubmed-author:NiBingB,
pubmed-author:ShiXinfuX,
pubmed-author:WangDongD,
pubmed-author:WangXiliangX,
pubmed-author:WuYuzhangY,
pubmed-author:YuXiaoX,
pubmed-author:ZhangLiangyanL,
pubmed-author:ZhangSongleS,
pubmed-author:ZhaoGuangyuG
|
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
681-90
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16152762-Animals,
pubmed-meshheading:16152762-Antibodies, Viral,
pubmed-meshheading:16152762-Antibody Specificity,
pubmed-meshheading:16152762-Cercopithecus aethiops,
pubmed-meshheading:16152762-Cytopathogenic Effect, Viral,
pubmed-meshheading:16152762-Disease Models, Animal,
pubmed-meshheading:16152762-Dose-Response Relationship, Drug,
pubmed-meshheading:16152762-Female,
pubmed-meshheading:16152762-Horses,
pubmed-meshheading:16152762-Immunization, Passive,
pubmed-meshheading:16152762-Immunoglobulin Fab Fragments,
pubmed-meshheading:16152762-Injections, Intraperitoneal,
pubmed-meshheading:16152762-Mice,
pubmed-meshheading:16152762-Neutralization Tests,
pubmed-meshheading:16152762-SARS Virus,
pubmed-meshheading:16152762-Severe Acute Respiratory Syndrome,
pubmed-meshheading:16152762-Vero Cells
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.
|
| pubmed:affiliation |
Department of Immunology, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|